INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

Pomerantz LLP is investigating potential securities fraud claims against EyePoint, Inc. following the failure of its DURAVYU drug candidate to meet primary efficacy endpoints in two Phase 3 clinical trials (LUGANO and LUCIA) for wet AMD treatment. The company's stock plummeted 66.98% on August 17, 2026, and an additional 85.28% on October 19, 2026, following the disappointing results. EyePoint announced significant cost-cutting measures including a 53% workforce reduction and termination of its wet AMD clinical program.